Market This pharma stock rose 21% after CLSA's rating change; Find out more Updated : November 18, 2019 03:47 PM IST Global brokerage CLSA upgraded Glenmark Pharma to 'buy' from 'sell' and raised its target price to Rs 410 per share from Rs 350 earlier. The stock gained as much as 8.7 percent to Rs 327.60 per share on BSE. Glenmark Pharma has advanced 16 percent in just 2 days post Q2 results. Subscribe to Moneycontrol PRO at just Rs.33/- per month for the first year. Use code SUPERPRO. Limited period offer. Available on Web and Android.